Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

Jan Gerard Maring (1) , Floris M. Wachters (2) , Monique Slijfer (3) , J. Marina Maurer (4) , H. Marike Boezen (5) , Donald R. A. Uges (4) , Elisabeth G. E. Vries (6) , Harry J. M. Groen (2)

1 Department of Pharmacy
2 Department of Pulmonary Medicine
3 Department of Pharmacy
4 Department of Pharmacy
5 Department of Epidemiology
6 Department of Medical Oncology

Mots clés: Gemcitabine; Cytidine deaminase; Pharmacogenetics; Pharmacokinetics; Genetic polymorphism

Jan Gerard Maring, Floris M. Wachters, Monique Slijfer, J. Marina Maurer, H. Marike Boezen, et al.. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. European Journal of Clinical Pharmacology, 2010, 66 (6), pp.611-617. ⟨10.1007/s00228-010-0799-0⟩. ⟨hal-00612989⟩